公司資料
Tango Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TNGX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
25.29 USD (-1.21%)
收盤價
最後更新: 2026年8月17日
3.11B USD
市值
股價為何變動
As of Aug 17, 2026, TNGX closed down 1.21% at $25.29. No new same-company headline was identified in the current news window.
公司概覽
Synthetic Lethality Oncology Company
Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss.
Vopimetostat
Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant tumors.
RAS(ON) Combination Strategy
The company is combining vopimetostat with RAS(ON) inhibitors in pancreatic and lung cancers carrying both MTAP deletion and RAS mutations.
TNG456
TNG456 is a next-generation PRMT5 inhibitor being evaluated in glioblastoma and other MTAP-deleted cancers, extending Tango's synthetic-lethality strategy into tumors where brain penetration is important.
未來催化劑
- Phase 1/2 data for vopimetostat in combination with RAS(ON) inhibitors at the ESMO Congress on October 23–27, 2026.
- Vopimetostat monotherapy data in lung cancer in the second half of 2026.
- Initial clinical data for TNG456 in glioblastoma and other cancers in the second half of 2026.
- Initiation of a Phase 1/2 study of vopimetostat plus ERAS-0015 in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。